Ignite Creation Date:
2024-05-06 @ 4:08 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04889118
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-09
First Post:
2021-05-12
Brief Title:
Safety and Efficacy Study of Pembrolizumab MK-3475 Combined With Lenvatinib MK-7902E7080 as First-line Intervention in Adults With Advanced Melanoma MK-7902-003E7080-G000-312LEAP-003-China Extension Study
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-07-14
Start Date Type:
ACTUAL
Primary Completion Date:
2023-01-18
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-11-08
Completion Date Type:
ESTIMATED
First Submit Date:
2021-05-12
First Submit QC Date:
May 12 2021
Study First Post Date:
2021-05-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2024-07-09
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-07-03
Last Update Post Date:
2024-07-09
Last Update Post Date Type:
ACTUAL